|
influenza |
13 |
|
h7n9 |
11 |
|
africa |
8 |
|
alveolar epithelial cells |
8 |
|
characterization |
8 |
|
coronaviruses |
8 |
|
mers-cov |
8 |
|
phenotype |
8 |
|
adult |
7 |
|
aged |
7 |
|
betacoronavirus |
7 |
|
blood |
7 |
|
cell-mediated immunity |
7 |
|
coronavirus infection |
7 |
|
cytokines - metabolism |
7 |
|
dna-directed dna polymerase - genetics - metabolism |
7 |
|
gene expression regulation, viral - physiology |
7 |
|
hemagglutinins - genetics - metabolism |
7 |
|
influenza a virus, h5n1 subtype - classification - genetics |
7 |
|
sars-cov-2 |
7 |
|
universal vaccine |
7 |
|
fractional factorial design |
6 |
|
hpai |
6 |
|
influenza polymerase |
6 |
|
pathogenesis |
6 |
|
risk assessment |
6 |
|
covid-19 |
5 |
|
deubiquitylases |
5 |
|
indirubin |
5 |
|
influenza a virus, h9n2 subtype - genetics - pathogenicity |
5 |
|
innate immune response |
5 |
|
ip-10 |
5 |
|
macrophages |
5 |
|
pneumocytes |
5 |
|
rig-i signaling |
5 |
|
rna replicase - genetics - metabolism |
5 |
|
rna virus |
5 |
|
ubiquitylation |
5 |
|
viral proteins - genetics - metabolism |
5 |
|
viral tropism |
5 |
|
virulence factors - genetics - metabolism |
5 |
|
animal experiment |
4 |
|
animal model |
4 |
|
animal tissue |
4 |
|
antibody dependent enhancement |
4 |
|
antigen binding |
4 |
|
antigenic cartography |
4 |
|
apoptosis |
4 |
|
avian influenza h5n1 virus |
4 |
|
bivalent rna vaccine |
4 |
|
bronchial epithelial cells |
4 |
|
cell cycle |
4 |
|
cell cycle arrest |
4 |
|
cyclin d3 |
4 |
|
extracellular signal-regulated map kinases - metabolism |
4 |
|
g1/s cyclin |
4 |
|
immune evasion |
4 |
|
infection-naïve |
4 |
|
influenza a virus - pathogenicity |
4 |
|
influenza a virus, h5n1 subtype |
4 |
|
m2 |
4 |
|
neutralization |
4 |
|
omicron subvariant |
4 |
|
p38 mitogen-activated protein kinases - antagonists & inhibitors - physiology |
4 |
|
pb2 |
4 |
|
pb2-627 |
4 |
|
polymerase |
4 |
|
protein degradation |
4 |
|
protein-protein interaction |
4 |
|
random mutagenesis |
4 |
|
restriction factor |
4 |
|
tumor necrosis factor-alpha - biosynthesis |
4 |
|
avian influenza a(h7n9) |
3 |
|
cell line |
3 |
|
epithelial cells - virology |
3 |
|
influenza a virus, h9n2 subtype - growth and development - physiology |
3 |
|
public health |
3 |
|
pulmonary alveoli - virology |
3 |
|
serology |
3 |
|
severity |
3 |
|
t cell response |
3 |
|
virus replication |
3 |
|
2.3.4.4 |
2 |
|
adaptive immunity; infectious disease; molecular biology; molecular diagnosis; virology. |
2 |
|
antibody |
2 |
|
antigenic imprinting |
2 |
|
apoptosis. |
2 |
|
avian influenza |
2 |
|
avian influenza - cytopathology. |
2 |
|
avian influenza - genetic aspects. |
2 |
|
b cell clonal expansion |
2 |
|
b cell repertoires |
2 |
|
bcr selection |
2 |
|
bcr sharing |
2 |
|
central nervous system infection |
2 |
|
china |
2 |
|
clinical |
2 |
|
cross-reactivity |
2 |
|
cytokines. |
2 |
|
dengue |
2 |
|
dynamics |
2 |
|
endemic |
2 |
|
ferrets |
2 |
|
h5n1 |
2 |
|
hemagglutinin (ha) |
2 |
|
highly pathogenic avian influenza |
2 |
|
hydrocephalus |
2 |
|
immune history |
2 |
|
immunity |
2 |
|
inflammation |
2 |
|
intra-host |
2 |
|
lung |
2 |
|
macrophages. |
2 |
|
neuraminidase (na) |
2 |
|
outbreak |
2 |
|
pao2/ fio2 |
2 |
|
pathogenicity |
2 |
|
phylogenetics |
2 |
|
signal transduction |
2 |
|
transcriptomic |
2 |
|
transmission |
2 |
|
vaccine |
2 |
|
variation |
2 |
|
virulence |
2 |
|
amino terminal sequence |
1 |
|
antibody isolation |
1 |
|
antigen bindingantigenicityarticlebinding affinity |
1 |
|
antigenicity |
1 |
|
bivalent vaccine |
1 |
|
bnt162b2 |
1 |
|
cerebrovascular disease |
1 |
|
coronavac |
1 |
|
cross-reactive |
1 |
|
egg-adaptive mutation |
1 |
|
epistasis |
1 |
|
hemagglutinin |
1 |
|
human coronavirus nl63 |
1 |
|
influenza virus |
1 |
|
jn.1 variant |
1 |
|
kp.2 variant |
1 |
|
molnupiravir |
1 |
|
mri |
1 |
|
neutralizing antibodies |
1 |
|
new subgenoty |
1 |
|
nirmatrelvir/ritonavir |
1 |
|
omicron xbb variant |
1 |
|
pepneumonia |
1 |
|
phylogenetic analysis |
1 |
|
post-covid-19 outcomes |
1 |
|
receptor binding |
1 |
|
t-cell immunity |
1 |
|
target trial emulation |
1 |
|
whole-genome sequencing |
1 |
|
xbb |
1 |
|
xbb.1.5 vaccines |
1 |
